CSF1R and glioblastoma: Specifically, the CSF-1R inhibitor BIZ954 enhances glioblastoma responsiveness to radiotherapy and synergizes with anti–PD-1 immune checkpoint blockade, effectively augmenting antitumor immunity (98, 99).